Duo Co-Founder, Dr. Song Li, Publishes Nanoparticle Review.
Duo Oncology Co-Founder Song Li Publishes Influential Review on Nanoparticle Therapeutics in Cancer Treatment.
PITTSBURGH (PRWEB) May 22, 2025 – Duo Oncology, a pioneering nanomedicine company dedicated to changing the cancer therapy landscape, proudly announces the publication of a comprehensive review article by its co-founder and co-inventor, Dr. Song Li, in Small Methods. The article, titled “Improving Tumor Targeting and Penetration for Nanoparticle‐Mediated Cancer Therapy,” provides a critical analysis of the current challenges and emerging strategies in nanoparticle-based cancer treatment.
As a world-renowned expert in nanoparticle drug delivery, Dr. Li’s work sheds light on innovative approaches to enhance tumor targeting and penetration, a key hurdle in the efficacy of nanoparticle-based therapies. The review discusses advancements in nanocarrier design, tumor microenvironment modulation, and precision medicine approaches that are shaping the future of oncology.
“At Duo Oncology, we are committed to transforming cancer treatment by harnessing cutting-edge technologies. Dr. Li’s insights reinforce our mission to develop more effective, patient-friendly therapeutics,” said Dr. Sam Rothstein, CEO of Duo Oncology. “This in-depth review underscores the novel ways in which researchers like Dr. Li are identifying shortcomings in nanoparticle therapy and developing innovative products that address those problems. There is a compelling need to improve cancer therapy and novel nanomedicines, like those in Duo Oncology’s pipeline, are making significant strides toward improving patient outcomes.”
The publication of this review aligns with Duo Oncology’s broader efforts to translate groundbreaking research into tangible clinical solutions. By addressing the complexities of nanoparticle design to improve transport and tumor penetration, Dr. Li’s work provides a foundation for the next generation of cancer therapies.
The full article is available online at Small Methods.
